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Extracellular matrix-evoked angiostasis and autophagy
within the tumor microenvironment represent two critical, but
unconnected, functions of the small leucine-rich proteoglycan,
decorin. Acting as a partial agonist of vascular endothelial
growth factor 2 (VEGFR2), soluble decorin signals via the energy
sensing protein, AMP-activated protein kinase (AMPK), in the
autophagic degradation of intracellular vascular endothelial
growth factor A (VEGFA). Here, we discovered that soluble
decorin evokes intracellular catabolism of endothelial VEGFA
that is mechanistically independent of mTOR, but requires an
autophagic regulator, paternally expressed gene 3 (PEG3). We
found that administration of autophagic inhibitors such as chloroquine or bafilomycin A1, or depletion of autophagy-related 5
(ATG5), results in accumulation of intracellular VEGFA, indicating that VEGFA is a basal autophagic substrate. Mechanistically, decorin increased the VEGFA clearance rate by augmenting autophagic flux, a process that required RAB24 member
RAS oncogene family (RAB24), a small GTPase that facilitates
the disposal of autophagic compartments. We validated these
findings by demonstrating the physiological relevance of this
process in vivo. Mice starved for 48 h exhibited a sharp
decrease in overall cardiac and aortic VEGFA that could be
blocked by systemic chloroquine treatment. Thus, our findings reveal a unified mechanism for the metabolic control of
endothelial VEGFA for autophagic clearance in response to
decorin and canonical pro-autophagic stimuli. We posit that
the VEGFR2/AMPK/PEG3 axis integrates the anti-angiogenic and pro-autophagic bioactivities of decorin as the
molecular basis for tumorigenic suppression. These results
support future therapeutic use of decorin as a next-generation protein therapy to combat cancer.

Decorin, an archetypical member of the small leucine-rich
proteoglycan gene family (1, 2), acts as a partial agonist for a
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diverse set of cell surface receptor-tyrosine kinases (RTKs)3
that directly regulate a surfeit of intracellular pathways via outside-in signaling (3–10). Classically, decorin evokes anti-oncogenic and angiostatic responses (11–13) in vitro (14, 15) and in
vivo (16 –18) via proteolytic degradation of oncogenes such as
␤-catenin, Myc (14), and HIF-1␣ (15), whereas concurrently
inducing tumor suppressors, i.e. p21WAF1 (19). Decorin is
unique among onco-suppressive agents (13) as it selectively and
simultaneously binds RTKs expressed in the stroma such as
VEGFR2 (20) and those expressed by the tumor parenchyma
such as EGFR and/or Met (21, 22). Decorin-deficient mice are
prone to tumorigenesis when either p53 is missing (23) or when
subjected to a Western high-fat diet (24, 25).
Mechanistically, decorin reduces intracellular, cell-associated, and secreted vascular endothelial growth factor A
(VEGFA) in a noncanonical manner and evokes the expression
and rapid secretion of thrombospondin-1 downstream of
VEGFR2 or Met (15, 26–29). The protracted suppression of
potent pro-angiogenic factors constitutes a key hallmark
of decorin as a soluble tumor repressor and emphasizes its
eponym as a guardian from the matrix (2, 30–33). Decorin has
been linked to metabolic reprogramming via regulation of cardiac O-␤-N-acetylglycosylation (34, 35).
Using high-resolution transcriptomics to identify decorinregulated genes in vivo, we discovered that paternally expressed
gene 3 (Peg3) was specifically induced within the Mus musculus
stroma in triple-negative breast carcinoma orthotopic tumor
xenografts treated with systemic delivery of decorin (18). Peg3
is a genomically-imprinted Krüpple-like zinc finger transcription factor possessing inherent tumor suppressor properties
(36, 37). Peg3 is commonly lost due to biallelic promoter
hypermethylation (38, 39) or loss of heterozygosity (40). Querying the ONCOMINE database (18), we found that Peg3
expression is substantially and significantly reduced in invasive
ductal breast carcinoma (41) and ductal breast carcinoma (42).
3

The abbreviations used are: RTK, receptor tyrosine kinase; AICAR, N1-(␤-Dribofuranosyl)-5-aminoimidazole-4 carboxamide; AMPK␣, 5⬘-AMP-activated protein kinase catalytic subunit ␣; ATG, autophagy regulated genes;
HAEC, human aortic endothelial cells; HIF-1␣, hypoxia-inducible factor 1
subunit ␣; HUVEC, Human umbilical vein endothelial cells; LC3, microtubule associated light chain 3; p62/SQSTM1, sequestome 1; VEGFA, vascular
endothelial growth factor-A; VEGFR2, vascular endothelial growth factor
receptor 2; PEG3, paternally expressed gene 3; CQ, chloroquine; PAER2,
porcine aortic endothelial cells overexpressing VEGFR2; DIC, differential
interference contrast; EGFR, epidermal growth factor receptor; mTOR,
mechanistic target of rapamycin; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HA, hemagglutinin; STAT, signal transducers and activators
of transcription; DAPI, 4⬘,6-diamidino-2-phenylindole; ANOVA, analysis of
variance.
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Autophagic clearance of intracellular VEGFA
Due to the functional similarities of Peg3 for the noncanonical
disruption of Wnt/␤-catenin signaling in a glycogen synthase
kinase 3␤-independent manner (43), which is strikingly akin to
the activity of decorin (14), Peg3 emerged as a prime candidate
for further study.
We discovered that Peg3 co-localizes and physically interacts
with the autophagic regulators LC3 and Beclin 1 (44) in
response to decorin and canonical autophagic stimuli in endothelial cells (20). Peg3 is necessary and sufficient to maintain
and evoke BECN1, MAP1LC3A, and TFEB expression (20, 28,
45, 46), and drives LC3-positive autophagosome formation and
autophagic flux (28). Moreover, we found that Peg3 is required
for thrombospondin-1 expression and secretion (28). Thus,
Peg3 may act as a nexus to parse anti-angiogenic and pro-autophagic signals for the concerted regulation of decorin-evoked
angiogenesis and autophagy.
Decorin actively signals via the VEGFR2 tyrosine kinase to
evoke autophagy (20, 47). Decorin differentially modulates
AMPK and mTOR phosphorylation, critical rheostats for
maintaining metabolic homeostasis (48 –51), to favor pro-autophagic outcomes. Indeed, AMPK and mTOR subsume
opposing roles in the governance of autophagic induction.
AMPK is required for autophagic initiation via ULK1/2 phosphorylation (51–54) and mTOR for autophagic inhibition and
termination (55, 56). We found prolonged phosphorylation of
the AMPK␣ catalytic subunit at Thr172 denoting activation
with a concurrent suppression of phosphorylated mTOR at
Ser2448 and its downstream effectors (Akt and p70S6K) in endothelial cells for up to 48 h (48). Importantly, decorin-evoked
endothelial cell autophagy occurs under nutrient-rich conditions, thereby designating decorin as a noncanonical stimulus
for evoking excessive autophagy.
Our understanding of the molecular mechanisms of VEGFs
regulating vascular homeostasis and angiogenesis has dramatically expanded in the past two decades (57, 58). Given that
decorin suppresses VEGFA with the concurrent induction of
autophagy via VEGFR2/AMPK␣/Peg3 in endothelial cells (20,
28, 46, 48), we hypothesized these pathways could converge to
catabolize intracellular VEGFA by autophagy as the mechanism for the onco-suppressive effects of decorin. In this study,
we found that decorin evokes the protracted catabolism
of intracellular VEGFA via endothelial cell autophagy in a
VEGFR2/AMPK/Peg3-dependent manner as the functional
apparatus to achieve angiostasis.

Results
Intracellular VEGFA protein levels are controlled by AMPK
We found via confocal imaging that decorin reduced intracellular VEGFA (Fig. 1A) in primary endothelial cells (HUVEC)
and human aortic endothelial cells immortalized by stable
expression of the human catalytic subunit of telomerase (TeloHAEC). VEGFA suppression proceeded in a VEGFR2-dependent manner as inhibition with the small molecule inhibitor,
SU5416 (59 –61) significantly abrogated the effect of decorin
(Fig. 1A). We previously found that exogenous decorin evokes
endothelial cell autophagy by activating the master energy sensor kinase, AMPK (52, 62, 63) by augmenting the phosphoryla-

tion of the ␣-catalytic subunit at Thr172 (48). We discovered
that treatment with Compound C (Dorsomorphin), a reversible
and selective AMPK␣ inhibitor (51), potently attenuated
VEGFA suppression (Fig. 1A), underscoring a role for the
VEGFR2/AMPK axis.
Next, we used AICAR, an analog of adenosine monophosphate that stimulates AMPK activity (64), to assess whether
AMPK alone was capable of modulating VEGFA. We verified
that AICAR potently activated AMPK as shown by increasing
levels of P-Thr172 (Fig. 1B), that peaked at 4 h (Fig. 2C). This is
in stark contrast to treating with vehicle only (DMSO), which
has no effect on P-AMPK␣ or VEGFA levels (Fig. S1, A and B).
We found that turning on AMPK via AICAR was sufficient to
increase Peg3 (Fig. 1, B and D), a master autophagic regulator
induced by decorin (20, 28, 46), and simultaneously decrease
intracellular VEGFA with a t1⁄2 of 2.6 h (Fig. 1, B and E). Notably,
immunofluorescence analysis showed that AICAR treatment
caused a similar induction of Peg3 (Fig. 1F) and concurrent
VEGFA suppression (Fig. 1G) with a comparable half-life (t1⁄2 ⫽
3.2 h). We then assessed the effect of AMPK on PEG3 and
VEGFA mRNA expression. AICAR dynamically increased
PEG3 mRNA peaking at ⬃2.5 h and then declining to basal
levels (Fig. 1H). Importantly, AICAR concomitantly decreased
VEGFA mRNA (Fig. 1I). However, the half-life of VEGFA
mRNA was nearly 5 h (t1⁄2 ⫽ 4.9 h), significantly longer (p ⫽
0.0014) than VEGFA protein (cf. Fig. 1, B and E).
We sought to better define a role of the AMPK kinase for the
differential regulation of Peg3 and VEGFA by treating HUVEC
with AICAR, either individually or in combination with Compound C. We validated AICAR function by immunoblotting for
P-Thr172 and found increased phosphorylation (Fig. 2, A and
B). Treatment with or without Compound C did not alter basal
or AICAR-induced P-Thr172 (Fig. 2, A and B). These data are
congruent with the established mechanism of AMPK␣ activation via canonical phosphorylation by the upstream LKB1/
MO25␣/STRAD1 trimeric kinase complex (50). Importantly,
Compound C significantly inhibited AICAR-mediated induction of Peg3 (p ⫽ 0.002, Fig. 2, A and C) and corresponding
VEGFA suppression (p ⫽ 0.006, Fig. 2, A and D). We confirmed
these biochemical findings using quantitative immunofluorescence under identical experimental conditions and found that
Compound C markedly prevented AICAR-evoked induction of
Peg3 (p ⫽ 0.0006, Fig. 2E) or reduction of VEGFA (p ⫽ 0.008,
Fig. 2F).
Collectively, these data support a dynamic and reciprocal
role of AMPK in inducing Peg3 and simultaneously decreasing
VEGFA in endothelial cells. Moreover, activating AMPK alone
with AICAR to mimic a low cellular energy state in an otherwise
enveloping nutrient-rich environment appears equivalent to
the decorin-dependent suppression of cellular VEGFA.
Endothelial VEGFA suppression is mTOR independent
We have previously shown that decorin turns off mTOR signaling in a protracted fashion by attenuating phosphorylation
at Ser2448 downstream of VEGFR2 and Akt, resulting in decreased activation of its effectors such as p70S6K (48).
Thus, we tested whether VEGFA suppression depended on
mTOR inhibition. To this end, we used Torin 1, a highly-speJ. Biol. Chem. (2020) 295(18) 6064 –6079
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Figure 1. Intracellular VEGFA and Peg3 are governed by AMPK in endothelial cells. A, gallery of confocal images in HUVEC (top) or TeloHAEC (bottom) treated in
combination with decorin (200 nM) ⫾ SU5416 (1 M) or Compound C (30 M) and immunostained for VEGFA (green) for 6 h. Nuclei (blue) were visualized with DAPI. Bar
⬃10 m. B, representative immunoblot of HUVEC treated with AICAR (500 M) at the indicated time points. C–E, quantification of targets as depicted in B. F and G,
semi-quantification of immunofluorescence signal intensity for VEGFA (F) or Peg3 (G) normalized to total cell number in HUVEC treated as in B. H and I, gene expression
of VEGFA (H) or PEG3 (I) in HUVEC as treated in B. GAPDH served as the loading control in B. DMSO served as vehicle for all experiments to account for SU5146,
Compound C, and AICAR. Data are reflective of several (n ⫽ 3– 4) independent biological replicates. Data are expressed as mean ⫾ S.E.

cific ATP competitive inhibitor of mTORC1 (65, 66). We assessed either p62/SQSTM1 (p62) or LC3 protein levels, two
established autophagic markers regulated by mTOR inhibition
(67). We found that Torin 1 dynamically modulated p62 in a
dose-dependent manner in HUVEC (Fig. 3, A and B) and
PAER2 (Fig. 3, C and D). Intriguingly, the responses were different between both models, with a maximal induction of p62 in
HUVEC occurring with as little as ⬃1 nM Torin 1, then decreasing at subsequently higher doses (Fig. 3, A and B). In PAER2,
which have been immortalized by the stable integration and
expression of VEGFR2, progressively increasing the amount of
Torin 1 significantly decreased p62/SQSTM1 (Fig. 3, C and D).
This was not a result of increased cell death as the internal
loading control (GAPDH) remained equal (Fig. 3, C and D) and
total cell numbers did not waver at the highest dose (500 nM)
administered (data not shown). However, despite positive modulation of p62 as a surrogate for autophagy, we found no change
of VEGFA with increasing amounts of Torin 1 in HUVEC (Fig.
3, A and B) or PAER2 (Fig. 3, C and D).

6066 J. Biol. Chem. (2020) 295(18) 6064 –6079

We next investigated the temporal effect of Torin 1 on VEGFA.
We used 20 nM Torin 1 as we previously found this to be most
effective dosage for autophagic induction in our system (68) and
LC3 as a positive control for mTOR inhibition because p62 levels
are only subtly modulated under this concentration of Torin 1 (Fig.
3, A and C). Similar time-dependent administration of Torin 1
induced dynamic LC3-II formation, the bioactive form of LC3,
in HUVEC that peaked at 1 h (Fig. 3, E and F). In PAER2, LC3-II
levels declined with Torin 1 treatment over time (Fig. 3, G and
H). However, similar to the dose-response, VEGFA was not
responsive to Torin 1 over time despite induction of autophagy
in either HUVEC (Fig. 3, E and F) or PAER2 (Fig. 3, G and H).
We complemented Torin 1 inhibition with INK128 (Sapanisertib), which more potently attenuates mTORC1/2 and has a
longer half-life than Torin 1 (69, 70). Under comparable experimental conditions, we found a similar trend in HUVEC where
p62 exhibited a dynamic induction, peaking at 0.1 nM followed
by a decline to baseline at higher concentrations (Fig. S2, A and
C). In PAER2, INK128 caused a progressive decline in p62 levels

Autophagic clearance of intracellular VEGFA

Figure 2. AMPK kinase activity is required for VEGFA and Peg3 modulation. A, representative immunoblots of HUVEC treated with AICAR (500 M) ⫾
Compound C (30 M) for 6 h. B–F, quantification of targets as immunostained in A. GAPDH served as the loading control for immunoblot in A. Data are reflective
of three independent biological replicates. Data are expressed as arbitrary units (A.U.) on a dot density plot. DMSO served as vehicle for the control condition.
Statistics were calculated via one-way ANOVA.

from baseline, akin to the effect of Torin 1, as INK128 concentrations increased (Fig. S2, B and D). Importantly, using this
more potent inhibitor of the mTOR complexes, VEGFA levels
were unperturbed in both endothelial cell types (Fig. S2, A–D).
Collectively, these data demonstrate an mTOR-independent
role of VEGFA modulation in endothelial cells utilizing pharmacological agents that mimic low-energy conditions, despite
lively regulation of established autophagic markers. Thus, bioenergetics-mediated regulation of intracellular VEGFA proceeds in an AMPK-dependent and mTOR-independent mechanism in endothelial cells.
VEGFA is sensitive to nutrient deprivation
As VEGFA is untouched by mTORC1/2 inhibition as a mimic of
the nutrient replete state, we performed nutrient deprivation in
PAER2 cells using Earle’s balanced salt solution (71) and evaluated
VEGFA over time. After confirming starvation-induced autophagy by increased P-AMPK␣ at Thr172 (data not shown), we
showed a concurrent decrease in p62 (Fig. S2, E and F). Importantly, we found a significant decrease in VEGFA, nearly mirroring
the profile of p62 over this same time frame (Fig. S2, E and F).
To evaluate the generality of the above results, we assessed
VEGFA regulation by pro-autophagic stimuli (AICAR, Torin 1,
and HBSS) in two other cell types, namely, human primary fibroblasts and NIH-3T3 immortalized mouse fibroblasts. Surprisingly,
in response to AICAR, p62 levels did not appreciably change in
either cell type (Fig. S3, A, C, B, and E). In contrast, AICAR significantly reduced VEGFA in human and mouse fibroblasts (Fig. S3,
A, D, B, and F), similar to endothelial cells. Treatment with Torin 1
reduced p62 (Fig. S3, A, C, B, and E) without a concomitant
decrease in VEGFA levels (Fig. S3, A, D, B, and F), akin to HUVEC
and PAER2. Nutrient deprivation via HBSS suppressed p62 levels
(Fig. S3, A, C, B, and E), whereas concurrently decreasing VEGFA
(Fig. S3, A, D, B, and F). Collectively, our findings highlight a general sensitivity of cellular VEGFA to pro-autophagic agents that is
not restricted to endothelia, further reinforcing the independence
of mTOR in this pathway.

Pro-autophagic stimuli evokes co-localization of VEGFA with
LC3 positive autophagosomes
We evaluated whether VEGFA would localize to autophagosomes using confocal imaging. We discovered that even basal
levels of VEGFA co-localized with LC3-positive autophagosomes (Fig. 4, A and B). However, 6 h treatment with decorin,
AICAR, or nutrient deprivation caused a marked increase in the
number and size of the VEGFA/LC3 dually-positive autophagosomes (Fig. 4, C, E, and G) as did the signal intensity ascertained by semi-quantitative line scanning profiles for each stimulus (Fig. 4, D, F, and H).
Next, we investigated the formation of VEGFA/LC3 duallypositive autophagosomes using differential interference contrast (DIC) microscopy on HUVEC challenged with decorin,
AICAR, or HBSS. We immunostained the cells with antibodies
against either LC3/VEGFA (Fig. 5, A–D) or Beclin 1/VEGFA
(Fig. 5, E–H) and found that all three stimuli significantly promoted the formation of dually-positive VEGFA/LC3 (Fig. 5,
B–D; Fig. S4A) or VEGFA/Beclin-1 (Fig. 5, F–H; Fig. S4B)
autophagosomes over basal conditions (Fig. 5, A and B; Fig. S4,
A and B). Moreover, we found discrete VEGFA/LC3 puncta
within large autophagosomes following decorin, AICAR, or
HBSS (Fig. 5, B–D, white arrows) that were absent under basal
conditions. Next, we evaluated VEGFA/p62 autophagosomal
positivity and found that decorin significantly increases the
number of VEGFA/p62 dually-positive autophagosomes as
well (Fig. S4, C and D). Mechanistically, we found that the formation of VEGFA/LC3-positive autophagosomes in HUVEC
was suppressed by treatment with the VEGFR2 kinase inhibitor
SU5416 (p ⬍ 0.001, Fig. 5, I and J). We validated the immunofluorescence by omitting the primary or secondary antibodies
in the presence or absence of BafA1 (Fig. S5). BafA1 served as a
positive control for LC3. Treating with BafA1 recapitulated the
augmented co-localization of VEGFA with LC3 (cf. Figs. 4 and
5; Fig. S5, A and B) over basal conditions. Omitting either the
primary (Fig. S5, C and D) or secondary (Fig. S5, E and F) antiJ. Biol. Chem. (2020) 295(18) 6064 –6079
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Figure 3. Endothelial VEGFA suppression is mTOR independent. A and B, representative immunoblots of increasing Torin 1 concentrations, as indicated, for
6 h in HUVEC (A) with corresponding quantification (B). C and D, identical experiment performed in PAER2 as in A and B. E and F, representative immunoblots
of Torin 1 (20 nM) at the indicated time points in HUVEC (E) with quantifications (F). G and H, identical experiment performed in PAER2 as in E and F. GAPDH
served as the loading control in all immunoblots (A, C, E, and G). In E–H, DMSO served as the vehicle for the 0-h control time point. All data are reflective of four
independent biological replicates. Data are expressed as mean ⫾ S.E.

bodies annulled the immunofluorescence signal, even in the
presence of BafA1. These data reinforce the robustness of our
immunofluorescence data.
Collectively, these imaging data posit VEGFA as an
autophagic substrate that is present in LC3- or p62-positive
autophagosomes under basal conditions. The incorporation
of VEGFA into autophagosomes was substantially augmented in response to decorin/VEGFR2 signaling, as well as
conventional pro-autophagic cues.
Peg3 drives VEGFA clearance via autophagy
As AMPK activation up-regulates Peg3 (cf. Fig. 1, B and C),
and Peg3 drives autophagosome formation (28), we postulated
that Peg3 could be directly involved in regulating VEGFA clearance via autophagy. Structurally, Peg3 is composed of an N-terminal SCAN domain required for protein–protein interactions
and an elongated C terminus of 12 C2H2 Krüpple-like zinc fingers interspersed with proline-rich regions potentially used for

6068 J. Biol. Chem. (2020) 295(18) 6064 –6079

DNA binding and transcriptional regulation (Fig. 6A) (36,
72–74). We transiently transfected PAER2 cells with empty
vector (pcDNA3.1), HA-PEG3, or HA-SCAN (Fig. 6A) and
verified their correct expression by immunoblotting using
anti-HA antibodies (Fig. 6B). Importantly, and in contrast to
either empty vector or SCAN-domain, overexpression of fulllength Peg3 drove the accumulation of VEGFA into LC3-positive autophagosomes (Fig. 6, C and D).
Next, we performed loss-of-function experiments to determine the role of Peg3 in promoting VEGFA-positive autophagosomes in response to decorin. We verified Peg3 knockdown
via RNAi and found a significant (p ⫽ 0.002) depletion (Fig.
S4E). Corroborating the gain-of-function experiments above,
we discovered that transient depletion of Peg3 abrogated the
ability of decorin to drive VEGFA into LC3-positive autophagosomes in HUVEC (Fig. 6E) vis à vis vehicles. Quantitation of
the Pearson’s coefficient of colocalization as a readout for dual
VEGFA/LC3 positivity supported (Fig. 6F) our confocal imag-

Autophagic clearance of intracellular VEGFA
ing that Peg3 is required for decorin-mediated VEGFA/LC3
autophagosome formation in endothelial cells. Collectively,
these data delineate a critical role for Peg3 as a necessary and
sufficient autophagic regulator to clear VEGFA by autophagy in
response to pro-autophagic stimuli.
Interfering with basal autophagic flux leads to an
accumulation of intracellular VEGFA

Figure 4. Pro-autophagic stimuli evokes co-localization of VEGFA with
LC3 positive autophagosomes. A, C, E, and G, gallery of confocal laser
microscopy images treated with vehicle (DMSO) (A), decorin (200 nM) (C),
AICAR (500 M) (E), or HBSS (G) for 6 h and immunostained for VEGFA
(green) and LC3 (red). Nuclei (blue) were visualized with DAPI. Bar ⬃10 m.
B, D, F, and H, line scanning profiles for each condition in the top set of
panels. Confocal imaging is representative of three independent biological replicates, each assaying ⬃10 fields per condition/biological replicate
with comparable outcomes.

Figure 5. Differential interference contrast microscopy of VEGFA-positive autophagosomes. A–D, gallery of DIC microscopy images in HUVEC
treated with pro-autophagic stimuli (vehicle, DMSO; decorin, 200 nM;
AICAR, 500 M) as listed for 6 h and immunostained with VEGFA (green) or
LC3 (red). E–H, identical experiment in HUVEC immunostained with VEGFA
(green) or Beclin 1 (red). Nuclei (blue) were visualized with DAPI. Bar ⬃10
m. I, representative DIC images of HUVEC treated with decorin (200
nm) ⫾ SU5416 (1 M) for 6 h and immunostained with VEGFA (green) or
LC3 (red). J, quantification of the number of autophagosomes per cell in
HUVEC as depicted in I. The graph is representative of four independent
biological replicates where ⬃40 cells per field were counted per biological
replicate. Statistics were calculated via one-way ANOVA (***, p ⬍ 0.001).

We observed that VEGFA co-localized under basal conditions with LC3 (cf. Figs. 4 and 5), Beclin 1 (cf. Fig. 5), and p62 (cf.
Fig. S4), suggesting that VEGFA could be directly degraded via
autophagy. We pharmacologically blocked autophagic flux
using bafilomycin A1 (BafA1 hereafter), a universally established method to assay autophagic processes (75–77). Mechanistically, BafA1 inhibits the vacuolar H⫹-ATPase to preclude
mature autophagosomes from fusing with lysosomes, thereby
giving a metric on the substrates undergoing autophagic degradation. Using PAER2 cells, we performed a BafA1 dose
response. Our positive control, proteolytic conversion of LC3-I
to LC3-II, which amasses following autophagic inhibition (76,
78, 79), increased in a concentration-dependent manner with as
little as 1 nM BafA1 (Fig. 7, A and B). Concurrent with LC3-II
induction, we found that VEGFA increased proportionally (Fig.
7, A and B). Notably, we found nearly identical results in
HUVEC (Fig. 7, C and D).
Next, we used a different autophagic inhibitor, chloroquine,
to assay the sensitivity of VEGFA to basal autophagy. Chloroquine (CQ), a lysosomotropic agent, has previously been
thought to prevent lysosomal acidification as a mechanism of
action (80). However, recently it has been shown that CQ inhibits autophagic flux by decreasing autophagosome-lysosome
fusion (81). Evaluating HUVEC with CQ, we found that LC3-II
increased (Fig. 7, E and F), validating CQ function, concomitantly with an accumulation of VEGFA (Fig. 7, E and F). Treating PAER2 cells with CQ resulted in a similar pattern wherein
p62 and VEGFA both increased (Fig. S6, A and B) in response to
autophagic inhibition.
Next, we complemented the pharmacological approach
with RNAi-mediated silencing of ATG5, an E1-like activating protease that processes LC3 for lipidation with phosphatidylethanolamine (82). Depleting ATG5 potently abrogates autophagosomal maturation leading to a cessation of
autophagy for flux analyses (83, 84). Loss of ATG5 results in
a build-up of LC3-I, the unprocessed form of LC3 (85). We
verified our siRNA and found a significant knockdown of
ATG5 in HUVEC (Fig. 7, G and H). ATG5 loss led to a
marked increase in LC3-I (Fig. 7, G and H), thus functionally
validating ATG5 silencing. Analogous to our findings, genetically silencing a critical enzyme for autophagosome maturation, we discovered a significant (p ⬍ 0.001) increase in
intracellular VEGFA with respect to our nontargeting vehicle (Fig. 7, G,H).
To determine the generality of our findings, we applied a
similar strategy to nonendothelial systems. We evaluated
NIH3T3 mouse fibroblasts with either BafA1 (Fig. S6, C and D)
or CQ (Fig. S6, E and F), with LC3-II conversion as a positive
control, and recapitulated the results insofar as VEGFA is
degraded by basal autophagic flux. Finally, we evaluated highlyJ. Biol. Chem. (2020) 295(18) 6064 –6079
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Figure 6. Peg3 drives VEGFA clearance via autophagy. A, schematic depiction of Peg3 architecture and engineered constructs. B, representative immunoblot validating expression of HA-tagged full-length Peg3, or HA-SCAN. WB, Western blot. C, immunofluorescence images of PAER2 transfected with equimolar
amounts of empty vector, full-length Peg3, or SCAN domain 48 h post-transfection. D, quantification of autophagosomes per cell in PAER2 as depicted in C.
Graph represents four independent biological replicates where ⬃50 cells per field were counted. E, confocal images of HUVEC transfected with siScr or siPeg3
(100 pM each) in combination with decorin (200 nM) for 6 h. F, calculation of Pearson’s coefficient of colocalization for the degree of overlap between VEGFA and
LC3 as demonstrated in E. In all images, immunostaining was performed for VEGFA (green) or LC3 (red). Nuclei (blue) were visualized with DAPI. Bar ⬃10 m.
GAPDH served as loading control in B. For Pearson’s coefficient in F, ⬃10 fields per experimental condition over three biological replicates were utilized.
Statistics were calculated via one-way ANOVA. N.S., not significant (***, p ⬍ 0.001).

malignant MDA-MB-231 triple-negative breast carcinoma
cells by treating with BafA1. We found increased LC3-II with
a build-up of VEGFA (Fig. S6, G and H). Collectively, these
pharmacological and genetic data indicate that VEGFA is
degraded by basal autophagy in a diverse number of cellular
systems and types.
Decorin evokes intracellular degradation of VEGFA via
autophagy and RAB24
A hallmark of decorin bioactivity is the dual property of being
anti-angiogenic (13, 15, 27, 32, 86, 87) and pro-autophagic (18,
20, 28, 46 – 48). Moreover, the Dcn gene itself is an autophagicinducible gene (88). We postulated that decorin-mediated
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autophagy is the mechanism by which intracellular VEGFA is
reduced.
We investigated this hypothesis by performing autophagic
flux assays in PAER2 and found that decorin significantly suppressed VEGFA levels (Fig. 8, A and B). Treatment with BafA1
alone increased both LC3-II and VEGFA above basal conditions (Fig. 8, A and B), further reinforcing our above findings (cf.
Fig. 7, A and B) that VEGFA is degraded by basal autophagy.
Combinatorial treatment of decorin and BafA1 increased
LC3-II levels beyond the levels expected of basal autophagy
(Fig. 8, A and B), corroborating the concept that decorin evokes
excessive autophagy by increasing autophagic flux. Critically,
VEGFA was no longer suppressed by decorin following

Autophagic clearance of intracellular VEGFA

Figure 7. Interfering with basal autophagic flux leads to an accumulation of intracellular VEGFA. A, representative immunoblots of PAER2 treated with
increasing concentrations of bafilomycin A1 (BafA1) for 6 h. B, quantification of targets as in A. C and D, immunoblot of HUVEC ⫾ BafA1 (500 nM) (C) and
quantification (D). E and F, immunoblot of HUVEC ⫾ chloroquine (30 M) for 6 h (E) and quantification (F). G and H, immunoblot depicting HUVEC following the
transient transfection of siScr or siATG5 (100 pM each) (G) and corresponding quantification of targets (H) as in G. GAPDH served as the loading control for
immunoblots depicted in A, C, E, and G. Data are reflective of four independent biological replicates. Data are expressed as arbitrary units (A.U.) on a dot density
plot. Statistics were calculated via two-tailed Student’s t test for D, F, and H.

autophagic inhibition with BafA1. Intracellular VEGFA levels
appeared modestly increased above basal levels with the combinatorial treatment indicating that decorin enhances the rate
of VEGFA catabolism (Fig. 8, A and B). These data indicate that
decorin clears intracellular VEGFA by inducing endothelial cell
autophagy.

Next, we investigated the small GTPase RAB24, a gene
induced by decorin via NanoString analysis.4 RAB24 has
recently been implicated in the autophagic pathway (89).

4

T. Neill, C. G. Chen, S. Buraschi, and R. V. Iozzo, unpublished dataset.
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Figure 8. Decorin evokes intracellular degradation of VEGFA via autophagy and RAB24. A, representative immunoblots of PAER2 cells treated with
decorin (200 nM) ⫾ BafA1 (500 nM) for 6 h. B, quantification of targets from A. C, representative immunoblots of PAER2 transiently transfected with siScr or
siRAB24 (100 pM each) ⫾ decorin (200 nM) for 6 h. D, quantification of targets from C. GAPDH served as loading control for immunoblots depicted in A and C.
Data are reflective of four independent biological replicates and expressed as arbitrary units (A.U.) on a dot density plot. Statistics were calculated via one-way
ANOVA (**, p ⬍ 0.01; ***, p ⬍ 0.001).

RAB24 facilitates autophagic clearance of components undergoing basal autophagy, but it does not aid in autophagosomal
formation, as depletion of RAB24 results in a significant
increase in late autophagic compartments (90). Therefore, as
VEGFA is degraded by autophagy and decorin promotes
increased autophagic flux of VEGFA and lysosomal biogenesis
via TFEB (46), we evaluated the role of RAB24. We silenced
RAB24 by RNAi and verified its depletion (Fig. 8, C and D). We
noted that decorin induced RAB24 by ⬃1.9-fold (p ⫽ 0.014)
(Fig. 8, C and D). Moreover, we found that LC3-I was significantly increased following loss of RAB24 indicating a role for
RAB24 in autophagosome maturation with no significant
changes seen in p62 (Fig. 8, C and D). Decorin reduced VEGFA
in PAER2 cells and this effect was abrogated following RAB24
silencing, recapitulating the findings from the flux assays (Fig.
8, C and D). Moreover, loss of RAB24 alone increased VEGFA
levels, corroborating the role of RAB24 in basal autophagic regulation and strengthening the shuttling of VEGFA in the
autophagic pathway for clearance (Fig. 8, C and D).
Taken together, these data illustrate that decorin promotes
VEGFA catabolism by autophagic clearance via RAB24 in
endothelial cells. This mechanism serves as a nexus by which
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decorin integrates and exerts its powerful anti-angiogenic and
pro-autophagic properties.
VEGFA is reduced in vivo by protracted fasting
To determine whether our in vitro results could also occur in
vivo, we fasted WT C57BL/6 mice for 48 h. We found that
VEGFA levels in both heart and aorta of fasted mice were significantly reduced compared with those fed ad libitum (Fig. 9,
A–D). As a positive control for starvation-induced autophagic
induction, we tested LC3-II levels and found a marked increase
in both cardiac and aortic tissues (Fig. 9, A–D). To provide
definitive proof for the in vivo autophagic catabolism of
VEGFA, we starved the mice for 48 h and treated them with CQ
(50 mg/kg) for the last 4 h. We found a significant increase in
VEGFA in cardiac and aortic tissues relative to starved mice
alone (Fig. 9, E–G). As a negative control, we evaluated
␤-catenin, a critical regulator of cell behavior in response to
Wnt signals (91) and canonical decorin target (14). We found
no significant changes in ␤-catenin levels in either the heart
(p ⫽ 0.456) or aorta (p ⫽ 0.433) following in vivo autophagy
inhibition (Fig. 9, E and F). Collectively, these results demonstrate that VEGFA is regulated in a nutrient-dependent manner
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Figure 9. VEGFA is reduced in vivo by protracted fasting. A, representative immunoblot of cardiac tissue from WT C57BL/6 mice following 48 h starvation.
B, quantification of immunoblot targets as in A. C, representative immunoblot of aortic tissue from WT C57BL/6 mice following 48 h starvation. D, quantification
of immunoblot targets as in C. E and F, representation immunoblot of in vivo autophagic flux in cardiac (E) or aortic (F) tissue following a 48-h starvation period
with concurrent systemic administration of chloroquine (50 mg/kg) for the last 4 h. G, quantification of VEGFA from the tissues as shown in E and F. GAPDH
served as a loading control for immunoblots depicted in A, C, E, and F. Data are reflective of four independent biological replicates and expressed as arbitrary
units (A.U.) on a dot density plot. Statistics were calculated via two-tailed Student’s t test.

in parenchymal tissues in vivo. These findings greatly reinforce
our in vitro data whereby VEGFA is governed by prevailing
nutrient conditions and by in vivo autophagic flux.

Discussion
Autophagic modulation by soluble extracellular matrix components is rapidly emerging as a common, conserved, and fundamental cellular mechanism intricately intertwined in health
and disease outcomes (9, 92, 93). In this study, we functionally
unified the anti-angiogenic and pro-autophagic properties of
decorin downstream of VEGFR2, AMPK, and Peg3 signaling in
endothelial cells and demonstrated that intracellular VEGFA is
catabolized via autophagy (Fig. 10).
Stimulation with the AMP-mimetic AICAR phenocopies the
effect of decorin. Our data support a reciprocal role of AMPK
that requires the inherent kinase activity of the catalytic ␣-subunit, to induce Peg3 and simultaneously decrease VEGFA in
endothelial cells at the protein level. Activating AMPK alone is
biologically equivalent to decorin-dependent suppression of
intracellular VEGFA, indicating that decorin and AMPK are in
the same signaling pathway, presumably downstream of
decorin/VEGFR2 interactions (Fig. 10). The precise connection
between VEGFR2 and phosphorylated AMPK remains elusive.
Considering the noncanonical activation of AMPK under

replete nutrient conditions (48) and cytosolic Ca2⫹ mobilization by decorin (94), it is feasible that decorin is engaging
the nucleotide-independent pathway to activate AMPK via
CAMKK2 (63) downstream of VEGFR2.
Decorin differentially modulates signaling to favor autophagic induction by attenuating mTOR at P-Ser2448 and inducing AMPK␣ at P-Thr172. It is known that mTOR can evoke
VEGFA expression via p70S6K1 activation and STAT3 nuclear
translocation to the VEGFA promoter (95, 96). Here, we demonstrate an mTOR-independent role of VEGFA suppression in
endothelial cells utilizing pharmacological agents that inhibit
the mTOR kinase and mimic low-energy conditions (97),
despite the lively regulation of LC3-I/-II and/or p62 (Fig. 10).
Thus, bioenergetics-mediated regulation of intracellular
VEGFA proceeds in an AMPK-dependent and mTOR-independent mechanism in endothelial cells and fibroblasts. It is
possible that decorin initiates autophagy solely via AMPK and
ULK1/2 (50, 51, 98) as decorin requires the class III phosphatidylinositol 3-kinase or Vps34 and Beclin 1-positive
complexes (20, 99) that are heavily involved in the early
stages of autophagic progression (100).
We found that conventional autophagic stimuli trigger
VEGFA incorporation into LC3- and Beclin 1-positive autoJ. Biol. Chem. (2020) 295(18) 6064 –6079
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Figure 10. Schematic depiction of decorin-evoked catabolism of VEGFA
via endothelial cell autophagy. Please refer to the text for additional details.
Star-shaped symbols denote lysosomal acid hydrolases.

phagosomes to a similar magnitude and frequency to that of
decorin. This process occurs downstream of VEGFR2 as tyrosine kinase inhibition prevents autophagosomal incorporation,
highlighting an active role of this RTK for the autophagic degradation of VEGFA in response to anti-angiogenic signals originating from the extracellular matrix. Decorin transduces signals through VEGFR2 that engage and augment catabolic hubs
for the degradation of powerful angiokines residing within the
cytosol. Interestingly, the overall levels of VEGFA are sensitive
to the ambient nutrient conditions as nutrient deprivation in
multiple cellular models representing diverse tissues, such as
endothelium, stromal, and triple negative breast cancer all
resulted in a significant decrease of VEGFA.
Mechanistically, the mobilization of VEGFA into LC3-positive autophagosomes requires the putative tumor suppressor
gene, Peg3 (Fig. 10). Transient depletion or overexpression of
full-length Peg3 is necessary and sufficient for the formation of
VEGFA/LC3-positive structures, respectively, whereas genetically ablating the C-terminal zinc finger domains abrogates this
process. Peg3 is capable of driving endothelial BECN1 gene
expression, a critical effector necessary for autophagosomes
biogenesis (101–103), and LC3-mediated autophagic flux (28).
Truncating the zinc finger domains may result in a loss of
BECN1 expression culminating in decreased autophagic flux,
thereby manifesting as reduced VEGFA/LC3 autophagosomes.
Alternately, loss of the zinc fingers may abrogate the scaffolding
function of Peg3, as its incorporation into Beclin 1-positive protein complexes (20) may be impaired resulting in dampened
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autophagosome formation. The exact molecular partners that
shuttle VEGFA into the autophagosome remain unidentified.
Bioinformatics analyses of the various VEGFA isoforms did not
identify a canonical LC3-interacting region that would enable
specific autophagosomal targeting; therefore, we cannot
exclude the possibility that VEGFA is merely a constituent of
the larger cytoplasmic milieu subject to bulk degradation by
macroautophagy.
Intracellular VEGFA is subject to autophagic flux as pharmacological inhibition with BafA1 or CQ, lysosomotropic agents
that block autophagosomal/lysosomal fusion, results in a considerable accumulation of VEGFA under basal conditions (Fig.
10). These findings were recapitulated by depleting ATG5, a
critical protease for LC3 maturation (85). Importantly, decorin
augments VEGFA flux, suggesting that this is a primary
pathway for intracellular control of VEGFA. Mechanistically,
decorin-evoked catabolism of VEGFA depends on RAB24, a
small GTPase recently implicated in autophagic progression,
particularly of substrates undergoing basal autophagy (89, 90).
However, whether the control of RAB24 is under the auspices
of the VEGFR2/AMPK/Peg3 signaling axis remains to be investigated (Fig. 10).
We validated our findings in vivo by demonstrating that starvation decreased VEGFA content in cardiac and aortic tissues,
suggesting physiological relevance for the metabolic control
over VEGFA. The starvation-mediated reduction of cardiac
and aortic VEGFA was blocked by systemically administrating
CQ, providing evidence for the in vivo role of autophagy in
VEGFA catabolism. The precise reservoir of VEGFA that is
being depleted, whether intracellular, cell-surface associated,
extracellular matrix, and/or blood, is currently unknown.
Therapeutic targeting of VEGFA with biological agents, such
as anti-VEGFA therapies using bevacizumab and ranibizumab,
have revolutionized the treatment of metastatic colorectal cancer and severe ophthalmological disorders (57, 58). Mechanistically, these agents function by inhibiting VEGFA thereby preventing rampant neovascularization (58). Considering the
effect of decorin in suppressing VEGFA via autophagic degradation, we recognize the potential clinical implications of
decorin administered as an adjuvant that specifically targets the
RTK-rich environment of the growing cancer (14). Moreover,
our general finding of VEGFA sensitivity to starvation and subsequent accumulation with autophagic inhibitors transcends
proteoglycan-driven endothelial cell autophagy. Starvationevoked VEGFA clearance may augment the clinical benefits of
caloric restriction as a potent modality to curb breast tumorigenesis by enhancing immunotherapies (105), radiation efficacy (106), and alleviating the metastatic burden (107, 108).
Collectively, we have integrated two critical properties of soluble decorin operating downstream of receptor binding for its
putative tumor repressor properties. At the nexus of this network is Peg3, which acts as a molecular conduit for coordinated
angiostasis and autophagic induction in response to decorin
and perhaps other autophagic stimuli derived from extracellular matrix interactions (109). These data further reinforce the
candidacy of decorin as a next-generation anti-angiogenic protein therapy (110) in the ongoing fight against cancer.
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Experimental procedures
Cells, chemicals, and general reagents
Primary HUVEC were obtained from Lifeline Cell Technology, grown in basal media supplemented with the VascuLife
EnGS LifeFactors Kit, also from Lifeline Cell Technology, and
used within the first five passages. Porcine aortic endothelial
cells overexpressing VEGFR2 (PAER2) were described previously (111, 112). Human aortic endothelial cells immortalized
by stable expression of the human catalytic subunit of telomerase (TeloHAEC), immortalized NIH-3T3 murine fibroblasts,
and human MDA-MB-231 triple-negative breast carcinoma
cells were procured from American Type Cell Culture. Cells
were grown at 37 °C in a 5% CO2 atmosphere in Dulbecco’s
modified Eagle’s medium containing 4.5 g/liter of glucose,
L-glutamine, and sodium pyruvate from Life Technologies and
supplemented with 5% fetal bovine serum from ThermoFisher
Scientific and 100 units/ml of penicillin/streptomycin from Life
Technologies. Dimethyl sulfoxide (DMSO) and Hanks’ balanced salt solution also came from ThermoFisher Scientific,
whereas Earle’s balanced salt solution was from HyClone. Rabbit monoclonal antibodies against GAPDH, HA, AMPK␣, and
P-AMPK␣ were obtained from Cell Signaling Technologies.
The rabbit polyclonal antibody against RAB24 was from Santa
Cruz Biotechnology. Rabbit polyclonal antibodies against p62
and LC3B were purchased from Sigma. Mouse monoclonal
antibodies against VEGFA and ATG5 were purchased from
Santa Cruz Biotechnology. A second mouse mAb against
VEGFA was purchased from Abcam. The rabbit anti-Beclin 1
and horseradish peroxidase-conjugated goat anti-rabbit and
donkey anti-mouse secondary antibodies were obtained from
EMD Millipore. A custom rabbit polyclonal antibody against
the N-terminal human SCAN domain of Peg3 (amino acids
164 –177) was generated by GenScript. Compound C, AICAR,
SU5416, bafilomycin A1, and chloroquine were purchased
from Sigma. Torin 1 was purchased from Tocris Biosciences.
INK128 was acquired from Cayman Chemicals. DMSO was
used as vehicle where appropriate for all experiments. All primary antibodies were used at 1:1,000 diluted in 1% BSA/TBST
except for GAPDH, which was used at 1:10,000 and VEGFA
(from Santa Cruz Biotechnology) was used at 1:500. For immunofluorescence, primary antibodies were used at 1:200 in 1%
BSA in PBS. Secondary antibodies for chemiluminescence were
used at 1:5,000 in the same buffer as above. The SuperSignal
West Pico Enhanced Chemiluminescence substrate was purchased from ThermoFisher Scientific (USA). Purification and
validation of human recombinant decorin free of any co-purifying contaminants can be found elsewhere (18).
Quantitative real-time PCR and analysis
Briefly, quantitative PCR was carried out on subconfluent
6-well-plates seeded with ⬃2 ⫻ 105 of HUVEC cells, treated per
experimental conditions, and lysed in 1 ml of TRIzol reagent
(Life Technologies). RNA isolation was carried out with Directzol RNA Miniprep Kit as per the manufacturer’s protocol
(Zymo Research). Total RNA (1 g) was annealed with oligo(dT) primers, and cDNA was synthesized using SuperScript
Reverse Transcriptase III (Life Technologies). Gene-specific

primer sets for Homo sapiens PEG3 and VEGFA were designed
and validated. Gene expression analysis was performed on a
Roche LightCycler 480-II and calculated with the comparative
⌬⌬Ct method. A full description can be found in Ref. 20.
Transient DNA expression and RNAi-mediated silencing
We transiently transfected PAER2 with empty vector
(pcDNA3.1) or plasmids encoding HA-Peg3 or HA-SCAN
using Lipofectamine 2000 (Life Technologies) in Opti-MEM
reduced serum media (Gibco). Expression was verified by
immunoblot using target-specific antibodies. A full description
of the DNA transfection protocol has been described elsewhere
(113). Cells were transiently transfected using Lipofectamine
RNAiMAX (Life Technologies) mixed with siRNA against
Peg3, ATG5, and RAB24 that were purchased from Santa Cruz
Biotechnology. The siRNA used represents a validated mixture
of 3–5 targeting oligonucleotides for each gene of interest.
Scrambled siRNA (sc-37007, Santa Cruz Biotechnology) served
as a control for all siRNA experiments presented herein. The
full protocol is described in Ref. 45.
Immunofluorescence, confocal laser microscopy, line
scanning, and Pearson’s coefficient of colocalization
Typically, ⬃5 ⫻ 104 HUVEC or PAER2 were plated on 0.2%
gelatin-coated 4-well-chamber slides (Nunc, ThermoFischer
Scientific) and grown to full confluence in their respective
growth media at 37 °C. Cells were treated as per the experimental conditions contained herein. Slides were incubated with
conjugated secondary antibodies such as: goat anti-rabbit IgG
Alexa Fluor威 488 and goat anti-mouse IgG Alexa Fluor威 564
(Life Technologies). Nuclei were visualized with DAPI (Vector
Laboratories). Immunofluorescence (104) and differential
interference contract images were acquired with a ⫻63, 1.3
oil-immersion objective installed on a LEICA DM5500B microscope with the Leica Application suite, advanced fluorescence
version 1.8 software from Leica Microsystems, Inc. Confocal
analyses were carried out utilizing a ⫻63, 1.3 oil-immersion
objective of a Zeiss LSM-780 confocal laser-scanning microscope with Zen Imaging Software. To determine colocalization
of proteins, Z-stack series were acquired maintaining the same
number of slices (n ⫽ 30). All images were then analyzed in
ImageJ (NIH) and Photoshop CS6 (Adobe Systems). Line scanning plots were generated using SigmaPlot software (Systat
Software). A full description can be found elsewhere (20).
Animal experiments
All animal experiments contained herein were performed as
per the Guide for Care and Use of Laboratory Animals and the
Institutional Animal Care and Use Committee of Thomas Jefferson University. C57BL/6 mice were purchased from Jackson
Laboratories. Both male and female mice and of various ages
ranging from 4 weeks to 6 months were used. Fasting experiments involved withholding food for 48 h, but water was
allowed ad libitum. Chloroquine (50 mg/kg in sterile dH2O)
was administered by intraperitoneal injection during the last
4 h of the starvation period. After animals were euthanized,
organs were removed and immediately snap-frozen in liquid
nitrogen. Cardiac and aortic tissues were homogenized, solubiJ. Biol. Chem. (2020) 295(18) 6064 –6079
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lized in T-PER Tissue Protein Extraction Buffer from ThermoFischer Scientific, and resolved by SDS-PAGE.
Statistical analysis
Immunoblots were quantified by scanning densitometry
using Scion Image software (NIH). Graphs were generated
using Sigma Stat 3.10. Experiments with three or more comparison groups were subjected to one-way ANOVA followed by a
Bonferroni post hoc test using the Systat Package of SigmaPlot
13.0. Differences were considered significant at two sided p ⬍
0.05.
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Author contributions—T. N., C. G. C., and R. V. I. conceptualization; T. N., C. G. C., S. B., and R. V. I. data curation; T. N., C. G. C.,
S. B., and R. V. I. formal analysis; T. N. and R. V. I. supervision; T. N.
and R. V. I. funding acquisition; T. N., C. G. C., S. B., and R. V. I.
investigation; T. N., C. G. C., and R. V. I. writing-original draft; T. N.
and R. V. I. project administration.
Acknowledgments—We thank L. Claesson-Welsh for providing the
porcine aortic endothelial cells overexpressing VEGFR2, C. Sharp and
S. Ward for their scientific contributions during the early stages of this
project, M. Johnson for providing the full-length HA-tagged Peg3, and
A. Torres for the HA-tagged Peg3 SCAN domain.
References
1. Iozzo, R. V., and Schaefer, L. (2015) Proteoglycan form and function: a
comprehensive nomenclature of proteoglycans. Matrix Biol. 42, 11–55
CrossRef Medline
2. Gubbiotti, M. A., Vallet, S. D., Ricard-Blum, S., and Iozzo, R. V. (2016)
Decorin interacting network: A comprehensive analysis of decorin-binding partners and their versatile functions. Matrix Biol. 55, 7–21 CrossRef
Medline
3. Iozzo, R. V., and Cohen, I. (1993) Altered proteoglycan gene expression
and the tumor stroma. Experientia 49, 447– 455 CrossRef Medline
4. Moreth, K., Iozzo, R. V., and Schaefer, L. (2012) Small leucine-rich proteoglycans orchestrate receptor crosstalk during inflammation. Cell Cycle 11, 2084 –2091 CrossRef Medline
5. Goldoni, S., Owens, R. T., McQuillan, D. J., Shriver, Z., Sasisekharan, R.,
Birk, D. E., Campbell, S., and Iozzo, R. V. (2004) Biologically active
decorin is a monomer in solution. J. Biol. Chem. 279, 6606 – 6612
CrossRef Medline
6. Neill, T., Schaefer, L., and Iozzo, R. V. (2015) Decoding the matrix: Instructive roles of proteoglycan receptors. Biochemistry 54, 4583– 4598
CrossRef Medline
7. Theocharis, A. D., Skandalis, S. S., Neill, T., Multhaupt, H. A., Hubo, M.,
Frey, H., Gopal, S., Gomes, A., Afratis, N., Lim, H. C., Couchman, J. R.,
Filmus, J., Sanderson, R. D., Schaefer, L., Iozzo, R. V., and Karamanos,
N. K. (2015) Insights into the key roles of proteoglycans in breast cancer
biology and translational medicine. Biochim. Biophys. Acta 1855,
276 –300 Medline
8. Schaefer, L. (2014) Proteoglycans, key regulators of cell-matrix dynamics. Matrix Biol. 35, 1–2 CrossRef Medline
9. Gubbiotti, M. A., and Iozzo, R. V. (2015) Proteoglycans regulate autophagy via outside-in signaling: an emerging new concept. Matrix Biol.
48, 6 –13 CrossRef Medline
10. Iozzo, R. V., and Gubbiotti, M. A. (2018) Extracellular matrix: the driving
force of mammalian diseases. Matrix Biol. 71–72, 1–9 Medline
11. Järveläinen, H., Sainio, A., and Wight, T. N. (2015) Pivotal role for
decorin in angiogenesis. Matrix Biol. 43, 15–26 CrossRef Medline

6076 J. Biol. Chem. (2020) 295(18) 6064 –6079

12. Neill, T., Schaefer, L., and Iozzo, R. V. (2016) Decorin as a multivalent
therapeutic agent against cancer. Adv. Drug Deliv. Rev. 97, 174 –185
CrossRef Medline
13. Neill, T., Schaefer, L., and Iozzo, R. V. (2015) An oncosuppressive role for
decorin. Mol. Cell. Oncol. 2, e975645 CrossRef Medline
14. Buraschi, S., Pal, N., Tyler-Rubinstein, N., Owens, R. T., Neill, T., and
Iozzo, R. V. (2010) Decorin antagonizes Met receptor activity and downregulates ␤-catenin and Myc levels. J. Biol. Chem. 285, 42075– 42085
CrossRef Medline
15. Neill, T., Painter, H., Buraschi, S., Owens, R. T., Lisanti, M. P., Schaefer,
L., and Iozzo, R. V. (2012) Decorin antagonizes the angiogenic network:
concurrent inhibition of Met, hypoxia inducible factor-1␣ and vascular
endothelial growth factor A and induction of thrombospondin-1 and
TIMP3. J. Biol. Chem. 287, 5492–5506 CrossRef Medline
16. Xu, W., Neill, T., Yang, Y., Hu, Z., Cleveland, E., Wu, Y., Hutten, R., Xiao,
X., Stock, S. R., Shevrin, D., Kaul, K., Brendler, C., Iozzo, R. V., and Seth,
P. (2015) The systemic delivery of an oncolytic adenovirus expressing
decorin inhibits bone metastasis in a mouse model of human prostate
cancer. Gene Ther. 22, 31– 40 Medline
17. Yang, Y., Xu, W., Neill, T., Hu, Z., Wang, C. H., Xiao, X., Stock, S. R.,
Guise, T., Yun, C. O., Brendler, C. B., Iozzo, R. V., and Seth, P. (2015)
Systemic delivery of an oncolytic adenovirus expressing decorin for the
treatment of breast cancer bone metastases. Hum. Gene Ther. 26,
813– 825 CrossRef Medline
18. Buraschi, S., Neill, T., Owens, R. T., Iniguez, L. A., Purkins, G., Vadigepalli, R., Evans, B., Schaefer, L., Peiper, S. C., Wang, Z. X., and Iozzo, R. V.
(2012) Decorin protein core affects the global gene expression profile of
the tumor microenvironment in a triple-negative orthotopic breast carcinoma xenograft model. PLoS ONE 7, e45559 CrossRef Medline
19. De Luca, A., Santra, M., Baldi, A., Giordano, A., and Iozzo, R. V. (1996)
Decorin-induced growth suppression is associated with upregulation of
p21, an inhibitor of cyclin-dependent kinases. J. Biol. Chem. 271,
18961–18965 CrossRef Medline
20. Buraschi, S., Neill, T., Goyal, A., Poluzzi, C., Smythies, J., Owens, R. T.,
Schaefer, L., Torres, A., and Iozzo, R. V. (2013) Decorin causes autophagy
in endothelial cells via Peg3. Proc. Natl. Acad. Sci. U.S.A. 110,
E2582–E2591 CrossRef Medline
21. Iozzo, R. V., Moscatello, D. K., McQuillan, D. J., and Eichstetter, I. (1999)
Decorin is a biological ligand for the epidermal growth factor receptor.
J. Biol. Chem. 274, 4489 – 4492 CrossRef Medline
22. Goldoni, S., Humphries, A., Nyström, A., Sattar, S., Owens, R. T., McQuillan, D. J., Ireton, K., and Iozzo, R. V. (2009) Decorin is a novel antagonistic ligand of the Met receptor. J. Cell Biol. 185, 743–754 CrossRef
Medline
23. Iozzo, R. V., Chakrani, F., Perrotti, D., McQuillan, D. J., Skorski, T., Calabretta, B., and Eichstetter, I. (1999) Cooperative action of germline mutations in decorin and p53 accelerates lymphoma tumorigenesis. Proc.
Natl. Acad. Sci. U.S.A. 96, 3092–3097 CrossRef Medline
24. Bi, X., Tong, C., Dockendorff, A., Bancroft, L., Gallagher, L., Guzman,
G., Iozzo, R. V., Augenlicht, L. H., and Yang, W. (2008) Genetic deficiency of decorin causes intestinal tumor formation through disruption of intestinal cell maturation. Carcinogenesis 29, 1435–1440
CrossRef Medline
25. Bi, X., Pohl, N. M., Qian, Z., Yang, G. R., Gou, Y., Guzman, G., KajdacsyBalla, A., Iozzo, R. V., and Yang, W. (2012) Decorin-mediated inhibition
of colorectal cancer growth and migration is associated with E-cadherin
in vitro and in mice. Carcinogenesis 33, 326 –330 CrossRef Medline
26. Grant, D. S., Yenisey, C., Rose, R. W., Tootell, M., Santra, M., and Iozzo,
R. V. (2002) Decorin suppresses tumor cell-mediated angiogenesis. Oncogene 21, 4765– 4777 CrossRef Medline
27. Neill, T., Jones, H. R., Crane-Smith, Z., Owens, R. T., Schaefer, L., and
Iozzo, R. V. (2013) Decorin induces rapid secretion of thrombospondin-1
in basal breast carcinoma cells via inhibition of Ras homolog gene family,
member A/Rho-associated coiled-coil containing protein kinase 1. FEBS
J. 280, 2353–2368 CrossRef Medline
28. Torres, A., Gubbiotti, M. A., and Iozzo, R. V. (2017) Decorin-inducible
Peg3 evokes beclin 1-mediated autophagy and thrombospondin 1-mediated angiostasis. J. Biol. Chem. 292, 5055–5069 CrossRef Medline

Autophagic clearance of intracellular VEGFA
29. Gubbiotti, M. A., Buraschi, S., Kapoor, A., and Iozzo, R. V. (2020) Proteoglycan signaling in tumor angiogenesis and endothelial cell autophagy. Semin. Cancer Biol. 68, 1– 8 Medline
30. Järveläinen, H., Puolakkainen, P., Pakkanen, S., Brown, E. L., Höök, M.,
Iozzo, R. V., Sage, H., and Wight, T. N. (2006) A role for decorin in
cutaneous wound healing and angiogenesis. Wound Rep. Reg. 14,
443– 452 CrossRef
31. Goldoni, S., Seidler, D. G., Heath, J., Fassan, M., Baffa, R., Thakur, M. L.,
Owens, R. T., McQuillan, D. J., and Iozzo, R. V. (2008) An anti-metastatic
role for decorin in breast cancer. Am. J. Pathol. 173, 844 – 855 CrossRef
Medline
32. Neill, T., Schaefer, L., and Iozzo, R. V. (2012) Decorin, a guardian from
the matrix. Am. J. Pathol. 181, 380 –387 CrossRef Medline
33. Mongiat, M., Buraschi, S., Andreuzzi, E., Neill, T., and Iozzo, R. V. (2019)
Extracellular matrix: the gatekeeper of tumor angiogenesis. Biochem. Soc.
Trans. 47, 1543–1555 CrossRef Medline
34. Gubbiotti, M. A., Seifert, E., Rodeck, U., Hoek, J. B., and Iozzo, R. V.
(2018) Metabolic reprogramming of murine cardiomyocytes during autophagy requires the extracellular nutrient sensor decorin. J. Biol. Chem.
293, 16940 –16950 CrossRef Medline
35. Vigetti, D., Caon, I., and Passi, A. (2018) A nutrient sentinel stands guard
outside the cell. J. Biol. Chem. 293, 16951–16952 CrossRef Medline
36. Kohda, T., Asai, A., Kuroiwa, Y., Kobayashi, S., Aisaka, K., Nagashima, G.,
Yoshida, M. C., Kondo, Y., Kagiyama, N., Kirino, T., Kaneko-Ishino, T.,
and Ishino, F. (2001) Tumour suppressor activity of human imprinted
gene PEG3 in a glioma cell line. Genes Cells 6, 237–247 CrossRef Medline
37. Nye, M. D., Hoyo, C., Huang, Z., Vidal, A. C., Wang, F., Overcash, F.,
Smith, J. S., Vasquez, B., Hernandez, B., Swai, B., Oneko, O., Mlay, P.,
Obure, J., Gammon, M. D., Bartlett, J. A., and Murphy, S. K. (2013)
Association between methylation of paternally expressed gene 3 (PEG3),
cervical intraepithelial neoplasia and invasive cervical cancer. PLoS ONE
8, e56325 CrossRef Medline
38. Dowdy, S. C., Gostout, B. S., Shridhar, V., Wu, X., Smith, D. I., Podratz,
K. C., and Jiang, S.-W. (2005) Biallelic methylation and silencing of paternally expressed gene 3 (PEG3) in gynecologic cancer cell lines. Gynecol. Oncol. 99, 126 –134 CrossRef Medline
39. Maegawa, S., Yoshioka, H., Itaba, N., Kubota, N., Nishihara, S., Shirayoshi, Y., Nanba, E., and Oshimura, M. (2001) Epigenetic silencing of PEG3
gene expression in human glioma cell lines. Mol. Carcinogenesis 31, 1–9
CrossRef
40. Feng, W., Marquez, R. T., Lu, Z., Liu, J., Lu, K. H., Issa, J.-P., Fishman,
D. M., Yu, Y., and Bast, R. C., Jr. (2008) Imprinted tumor suppressor
genes ARHI and PEG3 are the most frequently down-regulated in human
ovarian cancers by loss of heterozygosity and promoter methylation.
Cancer 112, 1489 –1502 CrossRef Medline
41. Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell,
G. W., Richardson, A. L., Polyak, K., Tubo, R., and Weinberg, R. A. (2007)
Mesenchymal stem cells within tumor stroma promote breast cancer
metastasis. Nature 449, 557–565 CrossRef Medline
42. Richardson, A. L., Wang, Z. C., De Nicolo, A., Lu, X., Brown, M., Miron,
A., Liao, X., Iglehart, J. D., Livingston, D. M., and Ganesan, S. (2006) X
chromosomal abnormalities in basal-like human breast cancer. Cancer
Cell 9, 121–132 CrossRef Medline
43. Jiang, X., Yu, Y., Yang, H. W., Agar, N. Y., Frado, L., and Johnson, M. D.
(2010) The imprinted gene PEG3 inhibits Wnt signaling and regulates
glioma growth. J. Biol. Chem. 285, 8472– 8480 CrossRef Medline
44. Levine, B., and Kroemer, G. (2019) Biological functions of autophagy
genes: a disease perspective. Cell 176, 11– 42 CrossRef Medline
45. Poluzzi, C., Casulli, J., Goyal, A., Mercer, T. J., Neill, T., and Iozzo, R. V.
(2014) Endorepellin evokes autophagy in endothelial cells. J. Biol. Chem.
289, 16114 –16128 CrossRef Medline
46. Neill, T., Sharpe, C., Owens, R. T., and Iozzo, R. V. (2017) Decorinevoked paternally expressed gene 3 (PEG3) is an upstream regulator of
the transcription factor EB (TFEB) in endothelial cell autophagy. J. Biol.
Chem. 292, 16211–16220 CrossRef Medline
47. Neill, T., Torres, A., Buraschi, S., and Iozzo, R. V. (2013) Decorin has an
appetite for endothelial cell autophagy. Autophagy 9, 1626 –1628
CrossRef Medline

48. Goyal, A., Neill, T., Owens, R. T., Schaefer, L., and Iozzo, R. V. (2014)
Decorin activates AMPK, an energy sensor kinase, to induce autophagy
in endothelial cells. Matrix Biol. 34, 46 –54 CrossRef Medline
49. Yang, Z., and Klionsky, D. J. (2010) Mammalian autophagy: core molecular machinery and signaling regulation. Curr. Opin. Cell Biol. 22,
124 –131 CrossRef Medline
50. Alers, S., Löffler, A. S., Wesselborg, S., and Stork, B. (2012) Role of
AMPK-mTOR-Ulk1/2 in the regulation of autophagy: crosstalk, shortcuts, and feedbacks. Mol. Cell. Biol. 32, 2–11 CrossRef Medline
51. Kim, J., Kundu, M., Viollet, B., and Guan, K.-L. (2011) AMPK and mTOR
regulate autophagy through direct phopshorylation of Ulk1. Nat. Cell
Biol. 13, 132–141 CrossRef Medline
52. Kim, J., and Guan, K. L. (2013) AMPK connects energy stress to PIK3C3/
VPS34 regulation. Autophagy 9, 1110 –1111 CrossRef Medline
53. Lee, J. W., Park, S., Takahashi, Y., and Wang, H.-G. (2010) The association of AMPK with ULK1 regulates autophagy. PLoS ONE 5, e15394
CrossRef Medline
54. Kuhajda, F. P. (2008) AMP-activated protein kinase and human cancer:
cancer metabolism revisited. Int. J. Obes. 32, S36 –S41 CrossRef
55. Rosenbluth, J. M., and Pietenpol, J. A. (2009) mTOR regulates autophagy-associated genes downstream of p73. Autophagy 5, 114 –116
CrossRef Medline
56. Yu, L., McPhee, C. K., Zheng, L., Mardones, G. A., Rong, Y., Peng, J., Mi,
N., Zhao, Y., Liu, Z., Wan, F., Hailey, D. W., Oorschot, V., Klumperman,
J., Baehrecke, E. H., and Lenardo, M. J. (2010) Termination of autophagy
and reformation of lysosomes regulated by mTOR. Nature 465, 942–946
CrossRef Medline
57. Apte, R. S., Chen, D. S., and Ferrara, N. (2019) VEGF in signaling and
disease: beyond discovery and development. Cell 176, 1248 –1264
CrossRef Medline
58. Ferrara, N., and Adamis, A. P. (2016) Ten years of anti-vascular endothelial growth factor therapy. Nat. Rev. Drug Discov. 15, 385– 403 CrossRef
Medline
59. Mendel, D. B., Schreck, R. E., West DC., Li.G, Strawn, L. M., Tanciongco,
S. S., Vasile, S., Shawver, L. K., and Cherrington, J. M. (2000) The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial
growth factor receptor phopshorylation and function. Clin. Cancer Res.
6, 4848 – 4858 Medline
60. Fong, T. A., Shawver, L. K., Sun, L., Tang, C., App, H., Powell, T. J., Kim,
Y. H., Schreck, R., Wang, X., Risau, W., Ullrich, A., Hirth, K. P., and
McMahon, G. (1999) SU5416 is a potent and selective inhibitor of the
vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits
tyrosine kinase catalysis, tumor vascularization, and growth of multiple
tumor types. Cancer Res. 59, 99 –106 Medline
61. Ban, H. S., Uno, M., and Nakamura, H. (2010) Suppression of hypoxiainduced HIF-1␣ accumulation by VEGFR inhibitors: different profiles of
AAL993, versus SU5416 and KRN633. Cancer Lett. 296, 17–26 CrossRef
Medline
62. Liang, J., and Mills, G. B. (2013) AMPK: a contextual oncogene or tumor
suppressor? Cancer Res. 73, 2929 –2935 CrossRef Medline
63. Garcia, D., and Shaw, R. J. (2017) AMPK: mechanisms of cellular energy
sensing and restoration of metabolic balance. Mol. Cell 66, 789 – 800
CrossRef Medline
64. Giri, S., Nath, N., Smith, B., Viollet, B., Singh, A. K., and Singh, I. (2004)
5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside
inhibits
proinflammatory response in glial cells: a possible role of AMP-activated
protein kinase. J. Neurosci. 24, 479 – 487 CrossRef Medline
65. Francipane, M. G., and Lagasse, E. (2013) Selective targeting of human
colon cancer stem-like cells by the mTOR inhibitor Torin-1. Oncotarget
4, 1948 –1962 Medline
66. Chen, C., Kapoor, A., and Iozzo, R. V. (2019) Methods for monitoring
matrix-induced autophagy. Methods Mol. Biol. 1952, 157–191 CrossRef
Medline
67. Mizushima, N. (2009) Methods for monitoring autophagy using GFPLC3 transgenic mice. Methods Enzymol. 452, 13–23 CrossRef Medline
68. Goyal, A., Gubbiotti, M. A., Chery, D. R., Han, L., and Iozzo, R. V. (2016)
Endorepellin-evoked autophagy contributes to angiostasis. J. Biol. Chem.
291, 19245–19256 CrossRef Medline

J. Biol. Chem. (2020) 295(18) 6064 –6079

6077

Autophagic clearance of intracellular VEGFA
69. Liu, Q., Thoreen, C., Wang, J., Sabatini, D., and Gray, N. S. (2009) mTOR
mediated anti-cancer drug discovery. Drug Discov. Today Ther. Strateg.
6, 47–55 CrossRef Medline
70. Hsieh, A. C., Liu, Y., Edlind, M. P., Ingolia, N. T., Janes, M. R., Sher, A.,
Shi, E. Y., Stumpf, C. R., Christensen, C., Bonham, M. J., Wang, S., Ren, P.,
Martin, M., Jessen, K., Feldman, M. E., et al. (2012) The translational
landscape of mTOR signalling steers cancer initiation and metastasis.
Nature 485, 55– 61 CrossRef Medline
71. Klionsky, D. J., Abdelmohsen, K., Abe, A., Abedin, M. J., Abeliovich, H.,
Acevedo, A. A., Adachi, H., Adams, C. M., Adams, P. D., Adeli, K., Adhihetty, P. J., Adler, S. G., Agam, G., Agarwal, R., Aghi, M. K., et al. (2016)
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12, 1–222 CrossRef Medline
72. Kuroiwa, Y., Kaneko-Ishino, T., Kagitani, F., Kohda, T., Li, L.-L., Tada,
M., Suzuki, R., Yokoyama, M., Shiroishi, T., Wakana, S., Barton, S. C.,
Ishino, F., and Surani, M. A. (1996) Peg3 imprinted gene on proximal
chromosome 7 encodes for a zinc finger protein. Nat. Genet. 12,
186 –190 CrossRef Medline
73. Edelstein, L. C., and Collins, T. (2005) The SCAN domain family of zinc
finger transcription factors. Gene 359, 1–17 CrossRef Medline
74. Rimsa, V., Eadsforth, T. C., and Hunter, W. N. (2013) Structure of the
SCAN domain of human paternally expressed gene 3 protein. PLoS ONE
8, e69538 CrossRef Medline
75. Moulis, M., and Vindis, C. (2017) Methods for measuring autophagy in
mice. Cells 6, e14 Medline
76. Galluzzi, L., Bravo-San Pedro, J. M., Levine, B., Green, D. R., and Kroemer, G. (2017) Pharmacological modulation of autophagy: therapeutic
potential and persisting obstacles. Nat. Rev. Drug Discov. 16, 487–511
CrossRef Medline
77. Gurney, M. A., Huang, C., Ramil, J. M., Ravindran, N., Andres, A. M., Sin, J.,
Linton, P. J., and Gottlieb, R. A. (2015) Measuring cardiac autophagic flux in
vitro and in vivo. Methods Mol. Biol. 1219, 187–197 CrossRef Medline
78. Martinez, J., Almendinger, J., Oberst, A., Ness, R., Dillon, C. P., Fitzgerald, P., Hengartner, M. O., and Green, D. R. (2011) Microtubule-associated protein 1 light chain 3␣ (LC3)-associated phagocytosis is required
for the efficient clearance of dead cells. Proc. Natl. Acad. Sci. U.S.A. 108,
17396 –17401 CrossRef Medline
79. Mizushima, N., Yoshimori, T., and Levine, B. (2010) Methods in mammalian autophagy research. Cell 140, 313–326 CrossRef Medline
80. Moore, B. R., Page-Sharp, M., Stoney, J. R., Ilett, K. F., Jago, J. D., and
Batty, K. T. (2011) Pharmacokinetics, pharmacodynamics, and allometric scaling of chloroquine in a murine malaria model. Antimicrob. Agents
Chemother. 55, 3899 –3907 CrossRef Medline
81. Mauthe, M., Orhon, I., Rocchi, C., Zhou, X., Luhr, M., Hijlkema, K. J.,
Coppes, R. P., Engedal, N., Mari, M., and Reggiori, F. (2018) Chloroquine
inhibits autophagic flux by decreasing autophagosome-lysosome fusion.
Autophagy 14, 1435–1455 CrossRef Medline
82. Singh, R., Kaushik, S., Wang, Y., Xiang, Y., Novak, I., Komatsu, M.,
Tanaka, K., Cuervo, A. M., and Czaja, M. J. (2009) Autophagy regulates
lipid metabolism. Nature 458, 1131–1135 CrossRef Medline
83. Katayama, H., Kogure, T., Mizushima, N., Yoshimori, T., and Miyawaki, A.
(2011) A sensitive and quantitative technique for detecting autophagic
events based on lysosomal delivery. Chem. Biol. 18, 1042–1052 CrossRef
Medline
84. Nishida, Y., Arakawa, S., Fujitani, K., Yamaguchi, H., Mizuta, T., Kanaseki, T., Komatsu, M., Otsu, K., Tsujimoto, Y., and Shimizu, S. (2009)
Discovery of Atg5/Atg7-independent alternative macroautophagy. Nature 461, 654 – 658 CrossRef Medline
85. Hara, T., Nakamura, K., Matsui, M., Yamamoto, A., Nakahara, Y., Suzuki-Migishima, R., Yokoyama, M., Mishima, K., Saito, I., Okano, H., and
Mizushima, N. (2006) Suppression of basal autophagy in neural cells
causes neurodegenerative disease in mice. Nature 441, 885– 889
CrossRef Medline
86. Karamanos, N. K., Piperigkou, Z., Theocharis, A. D., Watanabe, H., Franchi, M., Baud, S., Brézillon, S., Götté, M., Passi, A., Vigetti, D., RicardBlum, S., Sanderson, R. D., Neill, T., and Iozzo, R. V. (2018) Proteoglycan
chemical diversity drives multifunctional cell regulation and therapeutics. Chem. Rev. 118, 9152–9232 CrossRef Medline

6078 J. Biol. Chem. (2020) 295(18) 6064 –6079

87. Karamanos, N. K., Theocharis, A. D., Neill, T., and Iozzo, R. V. (2019)
Matrix modeling and remodeling: a biological interplay regulating tissue
homeostasis and diseases. Matrix Biol. 75–76, 1–11 Medline
88. Gubbiotti, M. A., Neill, T., Frey, H., Schaefer, L., and Iozzo, R. V. (2015)
Decorin is an autophagy-inducible proteoglycan and is required for
proper in vivo autophagy. Matrix Biol. 48, 14 –25 CrossRef Medline
89. Ylä-Anttila, P., and Eskelinen, E. L. (2018) Roles for RAB24 in autophagy
and disease. Small GTPases 9, 57– 65 CrossRef Medline
90. Ylä-Anttila, P., Mikkonen, E., Happonen, K. E., Holland, P., Ueno, T.,
Simonsen, A., and Eskelinen, E. L. (2015) RAB24 facilitates clearance of
autophagic compartments during basal conditions. Autophagy 11,
1833–1848 CrossRef Medline
91. Clevers, H. (2006) Wnt/␤-catenin signaling in development and disease.
Cell 127, 469 – 480 CrossRef Medline
92. Neill, T., Schaefer, L., and Iozzo, R. V. (2014) Instructive roles of extracellular matrix on autophagy. Am. J. Pathol. 184, 2146 –2153 CrossRef
Medline
93. Douglass, S., Goyal, A., and Iozzo, R. V. (2015) The role of perlecan and
endorepellin in the control of tumor angiogenesis and endothelial cell
autophagy. Connect. Tissue Res. 56, 381–391 CrossRef Medline
94. Patel, S., Santra, M., McQuillan, D. J., Iozzo, R. V., and Thomas, A. P.
(1998) Decorin activates the epidermal growth factor receptor and elevates cytosolic Ca2⫹ in A431 cells. J. Biol. Chem. 273, 3121–3124
CrossRef Medline
95. Yang, F., Zhang, W., Li, D., and Zhan, Q. (2013) Gadd45a suppresses
tumor angiogenesis via inhibition of the mTOR/STAT3 protein pathway. J. Biol. Chem. 288, 6552– 6560 CrossRef Medline
96. Dodd, K. M., Yang, J., Shen, M. H., Sampson, J. R., and Tee, A. R. (2015)
mTORC1 drives HIF-1␣ and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3. Oncogene 34, 2239 –2250
CrossRef Medline
97. Guertin, D. A., and Sabatini, D. M. (2009) The pharmacology of mTOR
inhibition. Sci. Signal. 2, pe24 Medline
98. Jung, C. H., Jun, C. B., Ro, S. H., Kim, Y. M., Otto, N. M., Cao, J., Kundu,
M., and Kim, D. H. (2009) ULK-Atg13-FIP200 complexes mediate
mTOR signaling to the autophagy machinery. Mol. Biol. Cell 20,
1992–2003 CrossRef Medline
99. Stjepanovic, G., Baskaran, S., Lin, M. G., and Hurley, J. H. (2017) Vps34
kinase domain dynamics regulate the autophagic PI 3-kinase complex.
Mol. Cell 67, 528 –534.e3 CrossRef Medline
100. Russell, R. C., Tian, Y., Yuan, H., Park, H. W., Chang, Y. Y., Kim, J., Kim,
H., Neufeld, T. P., Dillin, A., and Guan, K. L. (2013) ULK1 induces autophagy by phosphorylating Beclin-1 and activating VPS34 lipid kinase.
Nat. Cell Biol. 15, 741–750 CrossRef Medline
101. Kang, R., Zeh, H. J., Lotze, M. T., and Tang, D. (2011) The beclin 1
network regulates autophagy and apoptosis. Cell Death Differ. 18,
571–580 CrossRef Medline
102. Liang, X. H., Jackson, S., Seaman, M., Brown, K., Kempkes, B., Hibshoosh,
H., and Levine, B. (1999) Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 402, 672– 676 CrossRef Medline
103. Yue, Z., Jin, S., Yang, C., Levine, A. J., and Heintz, N. (2003) Beclin 1, an
authophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc. Natl. Acad. Sci. U.S.A. 100,
15077–15082 CrossRef Medline
104. Rudnicka, L., Varga, J., Christiano, A. M., Iozzo, R. V., Jimenez, S. A., and
Uitto, J. (1994) Elevated expression of type VII collagen in the skin of patients
with systemic sclerosis. J. Clin. Invest. 93, 1709 –1715 CrossRef Medline
105. Orillion, A., Damayanti, N. P., Shen, L., Adelaiye-Ogala, R., Affronti, H.,
Elbanna, M., Chintala, S., Ciesielski, M., Fontana, L., Kao, C., Elzey, B. D.,
Ratliff, T. L., Nelson, D. E., Smiraglia, D., Abrams, S. I., and Pili, R. (2018)
Dietary protein restriction reprograms tumor-associated macrophages
and enhances immunotherapy. Clin. Cancer Res. 24, 6383– 6395
CrossRef Medline
106. Saleh, A. D., Simone, B. A., Palazzo, J., Savage, J. E., Sano, Y., Dan, T., Jin,
L., Champ, C. E., Zhao, S., Lim, M., Sotgia, F., Camphausen, K., Pestell,
R. G., Mitchell, J. B., Lisanti, M. P., and Simone, N. L. (2013) Caloric
restriction augments radiation efficacy in breast cancer. Cell Cycle 12,
1955–1963 CrossRef Medline

Autophagic clearance of intracellular VEGFA
107. Jin, L., Lim, M., Zhao, S., Sano, Y., Simone, B. A., Savage, J. E., Wickstrom,
E., Camphausen, K., Pestell, R. G., and Simone, N. L. (2014) The metastatic potential of triple-negative breast cancer is decreased via caloric
restriction-mediated reduction of the miR-17⬃92 cluster. Breast Cancer
Res. Treat. 146, 41–50 CrossRef Medline
108. Simone, B. A., Dan, T., Palagani, A., Jin, L., Han, S. Y., Wright, C., Savage, J. E.,
Gitman, R., Lim, M. K., Palazzo, J., Mehta, M. P., and Simone, N. L. (2016)
Caloric restriction coupled with radiation decreases metastatic burden in
triple negative breast cancer. Cell Cycle 15, 2265–2274 CrossRef Medline
109. Garantziotis, S., and Savani, R. C. (2019) Hyaluronan biology: a complex
balancing act of structure, function, location and context. Matrix Biol.
78 –79, 1–10 Medline
110. Ricard-Blum, S., and Vallet, S. D. (2019) Fragments generated upon extracellular matrix remodeling: biological regulators and potential drugs.
Matrix Biol. 75–76, 170 –189 Medline

111. Goyal, A., Pal, N., Concannon, M., Paul, M., Doran, M., Poluzzi, C., Sekiguchi, K., Whitelock, J. M., Neill, T., and Iozzo, R. V. (2011) Endorepellin,
the angiostatic module of perlecan, interacts with both the ␣2␤1 integrin
and vascular endothelial growth factor receptor 2 (VEGFR2). J. Biol.
Chem. 286, 25947–25962 CrossRef Medline
112. Goyal, A., Poluzzi, C., Willis, C. D., Smythies, J., Shellard, A., Neill, T., and
Iozzo, R. V. (2012) Endorepellin affects angiogenesis by antagonizing
diverse VEGFR2-evoked signaling pathways: transcriptional repression
of HIF-1␣ and VEGFA and concurrent inhibition of NFAT1 activation.
J. Biol. Chem. 287, 43543– 43556 CrossRef Medline
113. Neill, T., Torres, A., Buraschi, S., Owens, R. T., Hoek, J. B., Baffa, R.,
and Iozzo, R. V. (2014) Decorin induces mitophagy in breast carcinoma cells via peroxisome proliferator-activated receptor ␥ coactivator-1␣ (PGC-1␣) and mitostatin. J. Biol. Chem. 289, 4952– 4968
CrossRef Medline

J. Biol. Chem. (2020) 295(18) 6064 –6079

6079

